This programme targets the leading causes of hospital-acquired infections
The ESKAPE pathogens collectively comprise the leading cause of hospital-acquired infections throughout the world. The pathogens are: E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter species. These pathogens are facing increasing rates of resistance, with the majority showing multi-drug resistance. A 2011 survey of US hospitals reported 722,000 hospital acquired ESKAPE pathogen infections resulting in 75,000 deaths annually.1
Our Discuva Platform allows us to uncover new bacterial targets for all of the ESKAPE pathogens. As a result, we have identified multiple series of compounds against new targets of the ESKAPE pathogens. These compounds are designed to be specific to a pathogen or infection, following the profile of our other new mechanism, narrow spectrum antibiotics. In addition, the Discuva Platform allows us to optimise compounds so that the pathogens are less likely to develop resistance against them.
As with our other antibiotics in development, we plan to develop our ESKAPE programme antibiotics to show advantages over the current standard of care and to meet the needs of patients and healthcare providers.
Our goal will be to replace the current standard of care in these disease areas and present valuable opportunities for large patient populations.
Reference : 1.Magill S. S., Edwards J. R., Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections. The New England Journal of Medicine. 2014;370(13):1198–1208.